Clinical trials: Adrenocortical Carcinoma
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Adrenocortical Carcinoma
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
This work will evaluate the effects of mitotane treatment on serum protein concentrations in patients treated for ACC with mitotane therapy and compare them to patients with an adrenal neoplasm and pregnant cohort.
- Trial name
- MitoS-FP (NCT05344027)
- Testing
- Mitotane
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Adrenocortical Carcinoma
Phase 1 Study of 68Ga-R8760
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
- Trial name
- NCT05999292
- Testing
- 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radionetics Oncology
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia
First-in-human Evaluation of [18F]CETO
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia, Adrenal Cushing Syndrome, Non-Secretory Adrenal Adenoma
- Trial name
- NCT05361083
- Testing
- F18CETO
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Adrenocortical Carcinoma
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the…
- Trial name
- NCT02015026
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Adrenal Incidentaloma, Adrenocortical Carcinoma
Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Standard diagnostic work-up for adrenal incidentalomas (AI) consists of periodical biochemical analysis and CT-scanning in case the initial work-up does not demonstrate the presence of hormonal hypersecretion or adrenocortical…
- Trial name
- SERENDIPITY (NCT02324647)
- Where
- Netherlands
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Adrenocortical Carcinoma, Cushing's Syndrome
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice.
- Trial name
- NCT00457587
- Where
- Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Wuerzburg